Safety and Effectiveness of Disease-Modifying Therapies After Switching From Natalizumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Multiple Sclerosis (Houndmills, Basingstoke, England)
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and effectiveness of disease-modifying therapies after switching from natalizumab
Mult. Scler. 2024 Jul 01;30(8)1026-1035, M Zeineddine, R Al-Roughani, S Farouk Ahmed, S Khoury, N El-Ayoubi, A Al-Mahdawi, J Al-Khabouri, A Al-Asmi, A Chentouf, J Inshasi, R Gouider, S Mrabet, N Shalaby, J Massouh, F Mohamed Ramzy Hasan Mohamed, A Al-Hajje, P Salameh, H Dimassi, F Boumediene, B YamoutFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.